AstraZeneca prepares to live with the IRA, shifting focus of arguments to orphan drug changes

NEW YORK — As­traZeneca may be get­ting ready to live with the In­fla­tion Re­duc­tion Act.

On Fri­day morn­ing, CEO Pas­cal So­ri­ot told re­porters that the drug­mak­er is most fo­cused on get­ting the 2022 law ad­just­ed, not in­val­i­dat­ed. His com­ments are the most di­rect yet from a ma­jor phar­ma CEO about a fu­ture in which the IRA is not ful­ly over­turned by the courts, as sev­er­al drug­mak­ers have sued to try and do.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.